Cargando…

Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial

Background: Butyric acid’s effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD. Methods: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrzak, Anna, Banasiuk, Marcin, Szczepanik, Mariusz, Borys-Iwanicka, Agnieszka, Pytrus, Tomasz, Walkowiak, Jarosław, Banaszkiewicz, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414716/
https://www.ncbi.nlm.nih.gov/pubmed/36014789
http://dx.doi.org/10.3390/nu14163283
_version_ 1784776056408899584
author Pietrzak, Anna
Banasiuk, Marcin
Szczepanik, Mariusz
Borys-Iwanicka, Agnieszka
Pytrus, Tomasz
Walkowiak, Jarosław
Banaszkiewicz, Aleksandra
author_facet Pietrzak, Anna
Banasiuk, Marcin
Szczepanik, Mariusz
Borys-Iwanicka, Agnieszka
Pytrus, Tomasz
Walkowiak, Jarosław
Banaszkiewicz, Aleksandra
author_sort Pietrzak, Anna
collection PubMed
description Background: Butyric acid’s effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD. Methods: This was a prospective, randomized, placebo-controlled multicenter study. Patients aged 6–18 years with colonic Crohn’s disease or ulcerative colitis, who received standard therapy depending on the disease’s severity, were randomized to receive 150 mg sodium butyrate twice a day (group A) or placebo (group B). The primary outcome was the difference in disease activity and fecal calprotectin concentration between the two study groups measured at 12 weeks of the study. Results: In total, 72 patients with initially active disease completed the study, 29 patients in group A and 43 in group B. At week 12 of the study, the majority of patients achieved remission. No difference in remission rate or median disease activity was found between the two groups (p = 0.37 and 0.31, respectively). None of the patients reported adverse events. Conclusions: A 12-week supplementation with sodium butyrate, as adjunctive therapy, did not show efficacy in newly diagnosed children and adolescents with IBD.
format Online
Article
Text
id pubmed-9414716
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94147162022-08-27 Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial Pietrzak, Anna Banasiuk, Marcin Szczepanik, Mariusz Borys-Iwanicka, Agnieszka Pytrus, Tomasz Walkowiak, Jarosław Banaszkiewicz, Aleksandra Nutrients Article Background: Butyric acid’s effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD. Methods: This was a prospective, randomized, placebo-controlled multicenter study. Patients aged 6–18 years with colonic Crohn’s disease or ulcerative colitis, who received standard therapy depending on the disease’s severity, were randomized to receive 150 mg sodium butyrate twice a day (group A) or placebo (group B). The primary outcome was the difference in disease activity and fecal calprotectin concentration between the two study groups measured at 12 weeks of the study. Results: In total, 72 patients with initially active disease completed the study, 29 patients in group A and 43 in group B. At week 12 of the study, the majority of patients achieved remission. No difference in remission rate or median disease activity was found between the two groups (p = 0.37 and 0.31, respectively). None of the patients reported adverse events. Conclusions: A 12-week supplementation with sodium butyrate, as adjunctive therapy, did not show efficacy in newly diagnosed children and adolescents with IBD. MDPI 2022-08-11 /pmc/articles/PMC9414716/ /pubmed/36014789 http://dx.doi.org/10.3390/nu14163283 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pietrzak, Anna
Banasiuk, Marcin
Szczepanik, Mariusz
Borys-Iwanicka, Agnieszka
Pytrus, Tomasz
Walkowiak, Jarosław
Banaszkiewicz, Aleksandra
Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial
title Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial
title_full Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial
title_fullStr Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial
title_full_unstemmed Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial
title_short Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases—Randomized Placebo-Controlled Multicenter Trial
title_sort sodium butyrate effectiveness in children and adolescents with newly diagnosed inflammatory bowel diseases—randomized placebo-controlled multicenter trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414716/
https://www.ncbi.nlm.nih.gov/pubmed/36014789
http://dx.doi.org/10.3390/nu14163283
work_keys_str_mv AT pietrzakanna sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial
AT banasiukmarcin sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial
AT szczepanikmariusz sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial
AT borysiwanickaagnieszka sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial
AT pytrustomasz sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial
AT walkowiakjarosław sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial
AT banaszkiewiczaleksandra sodiumbutyrateeffectivenessinchildrenandadolescentswithnewlydiagnosedinflammatoryboweldiseasesrandomizedplacebocontrolledmulticentertrial